# Aleix Prat

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aleix-prat/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,608 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 91 |
| i10-index | 296 |
| Last Known Institution | Breast Cancer Research Foundation |
| OpenAlex ID | https://openalex.org/A5089513581 |
| ORCID iD | https://orcid.org/0000-0003-2377-540X |
| Works | 1,346 |

## Researcher papers

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Immune-related adverse events of checkpoint inhibitors](https://scholariq.org/papers/immune-related-adverse-events-of-checkpoint-inhibitors/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031](https://scholariq.org/papers/randomized-phase-ii-neoadjuvant-comparison-between-letrozole-anastrozole-and/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)
- [Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models](https://scholariq.org/papers/targeting-chk1-in-p53-deficient-triple-negative-breast-cancer-is-therapeutically/)
- [6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)](https://scholariq.org/papers/6th-and-7th-international-consensus-guidelines-for-the-management-of-advanced/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Breast Cancer Research Foundation](https://scholariq.org/institutions/breast-cancer-research-foundation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.